Total Credits: 1.0 including 1.0 AOA Category 1-A Credit(s), 1.0 AMA PRA Category 1 Credit(s)™
Optimizing opioid management while mitigating risk in the chronic pain patient
Patrick Hogan, DO
Learning Objectives:
Dr. Hogan is on the Speakers’ Bureau for Aspen Medical.
Accreditation
The Arizona Osteopathic Medical Association (AOMA) is accredited by the American Osteopathic Association (AOA) to provide osteopathic continuing medical education for physicians.
The AOMA designates this activity for a maximum of 1.0 hours of AOA Category 1-A credits and will report CME and specialty credits commensurate with the extent of the physician's participation in this activity.
The Arizona Osteopathic Medical Association (AOMA) is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.
The AOMA designates this live activity for a maximum of 1.0 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
AOMA Grievance Policy: The Arizona Osteopathic Medical Association strives to provide continuing medical education programs to fulfill the needs of the attendees and to meet the AOA Accreditation Requirements and ACCME Accreditation Requirements. Comments, questions, or complaints should be submitted in writing to Teresa Roland, Director of Education, by mail to AOMA, 3039 W Peoria Ave, Suite C102-158, Phoenix, AZ 85029, or email teresa@azosteo.org.
| Optimizing opioid management while mitigating risk in the chronic pain patient (2.4 MB) | 20 Pages | Available after Purchase |
Pat Hogan is a neurologist in Tacoma focusing on the treatment of movement disorders and migraine. He is the founder of Puget Sound Neurology integrative care center where treatment of patients follows the Osteopathic principles of a holistic comprehensive approach for each individual. Pertinent to today’s topic is that he was the first person trained in Washington State to administer Botox injection therapy in 1990 that has developed into the highest use of all 4 types of botulinum toxins throughout the Northwest for the indications that he will discuss this morning.